Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 20/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 20/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.60 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.60 |
| ▸ | HTR2C | P28335 | 2/20 | 0.60 |
| ▸ | HTR2B | P41595 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3057591 | 1.00 | HRH1 (0.64) | HRH1KCNH2CYP3A4CYP2D6CHRM1 | |
| SCHEMBL1148995 | 0.88 | HRH1 (0.60) | HRH1KCNH2CYP3A4CYP2D6CHRM1 | |
| SCHEMBL3045766 | 0.85 | HRH1 (0.67) | HRH1KCNH2CYP3A4CYP2D6CHRM1 | |
| SCHEMBL3045770 | 0.85 | HRH1 (0.67) | HRH1KCNH2CYP3A4CYP2D6CHRM1 | |
| SCHEMBL3053140 | 0.85 | HRH1 (0.71) | HRH1KCNH2CYP3A4CYP2D6CHRM1 | |
| SCHEMBL3040410 | 0.85 | HRH1 (0.68) | HRH1KCNH2CYP3A4CYP2D6CHRM1 | |
| SCHEMBL3054505 | 0.85 | HRH1 (0.68) | HRH1KCNH2CYP3A4CYP2D6CHRM1 | |
| SCHEMBL1149079 | 0.84 | HRH1 (0.64) | HRH1KCNH2CYP3A4CYP2D6CHRM1 | |
| SCHEMBL3041500 | 0.84 | HRH1 (0.62) | HRH1KCNH2CYP3A4CYP2D6CHRM1 | |
| SCHEMBL3061376 | 0.84 | HRH1 (0.62) | HRH1KCNH2CYP3A4CYP2D6CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222349-A1 | QUINOLINE DERIVATIVES USED TO TREAT INFLAMMATORY AND ALLERGIC DISEASES | GLAXO GROUP LIMITED (GB) | 2010-09-02 | — | — | US | disclosed |
| US-20090270355-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270355-A1 | Compounds | CMA1, HRH4, CCL11 | HRH1 7/4885KCNH2 884/4885CYP3A4 253/4885 |
| US-20100222349-A1 | QUINOLINE DERIVATIVES USED TO TREAT INFLAMMATORY AND ALLERGIC DISEASES | IL5, HRH2, HRH1 | HRH1 3/4885KCNH2 1186/4885CYP3A4 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.